Treatment of post-viral olfactory dysfunction: an evidence-based review with recommendations.
budesonide
evidence-based medicine
olfaction disorders
olfactory training
smell
viral infection
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
22
04
2020
revised:
07
05
2020
accepted:
12
05
2020
pubmed:
23
6
2020
medline:
30
9
2021
entrez:
23
6
2020
Statut:
ppublish
Résumé
Post-viral olfactory dysfunction (PVOD) is one of the most common causes of olfactory loss. Despite its prevalence, optimal treatment strategies remain unclear. This article provides a comprehensive review of PVOD treatment options and provides evidence-based recommendations for their use. A systematic review of the Medline, Embase, Cochrane, Web of Science, Scopus, and Google Scholar databases was completed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies with defined olfactory outcomes of patients treated for PVOD following medical, surgical, acupuncture, or olfactory training interventions were included. The Clinical Practice Guideline Development Manual and Conference on Guideline Standardization (COGS) instrument recommendations were followed in accordance with a previously described, rigorous, iterative process to create an evidence-based review with recommendations. From 552 initial candidate articles, 36 studies with data for 2183 patients with PVOD were ultimately included. The most common method to assess olfactory outcomes was Sniffin' Sticks. Broad treatment categories included: olfactory training, systemic steroids, topical therapies, a variety of heterogeneous non-steroidal oral medications, and acupuncture. Based on the available evidence, olfactory training is a recommendation for the treatment of PVOD. The use of short-term systemic and/or topical steroids is an option in select patients after careful consideration of potential risks of oral steroids. Though some pharmacological investigations offer promising preliminary results for systemic and topical medications alike, a paucity of high-quality studies limits the ability to make meaningful evidence-based recommendations for the use of these therapies for the treatment of PVOD.
Sections du résumé
BACKGROUND
Post-viral olfactory dysfunction (PVOD) is one of the most common causes of olfactory loss. Despite its prevalence, optimal treatment strategies remain unclear. This article provides a comprehensive review of PVOD treatment options and provides evidence-based recommendations for their use.
METHODS
A systematic review of the Medline, Embase, Cochrane, Web of Science, Scopus, and Google Scholar databases was completed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies with defined olfactory outcomes of patients treated for PVOD following medical, surgical, acupuncture, or olfactory training interventions were included. The Clinical Practice Guideline Development Manual and Conference on Guideline Standardization (COGS) instrument recommendations were followed in accordance with a previously described, rigorous, iterative process to create an evidence-based review with recommendations.
RESULTS
From 552 initial candidate articles, 36 studies with data for 2183 patients with PVOD were ultimately included. The most common method to assess olfactory outcomes was Sniffin' Sticks. Broad treatment categories included: olfactory training, systemic steroids, topical therapies, a variety of heterogeneous non-steroidal oral medications, and acupuncture.
CONCLUSION
Based on the available evidence, olfactory training is a recommendation for the treatment of PVOD. The use of short-term systemic and/or topical steroids is an option in select patients after careful consideration of potential risks of oral steroids. Though some pharmacological investigations offer promising preliminary results for systemic and topical medications alike, a paucity of high-quality studies limits the ability to make meaningful evidence-based recommendations for the use of these therapies for the treatment of PVOD.
Identifiants
pubmed: 32567798
doi: 10.1002/alr.22624
pmc: PMC7361320
doi:
Substances chimiques
Steroids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1065-1086Informations de copyright
© 2020 ARS-AAOA, LLC.
Références
Laryngoscope. 2008 Sep;118(9):1681-6
pubmed: 18677278
Int Forum Allergy Rhinol. 2016 Mar;6(3):299-307
pubmed: 26624966
Rhinology. 1995 Sep;33(3):162-5
pubmed: 8560170
Int Forum Allergy Rhinol. 2019 Feb;9(2):165-176
pubmed: 30472771
Laryngoscope. 2007 Feb;117(2):272-7
pubmed: 17277621
Clin Otolaryngol. 2017 Dec;42(6):1295-1302
pubmed: 28339165
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Ann Intern Med. 2003 Sep 16;139(6):493-8
pubmed: 13679327
Rhinol Suppl. 2017 Mar;54(26):1-30
pubmed: 29528615
Am J Med Sci. 2009 Jun;337(6):396-406
pubmed: 19359985
Med Mal Infect. 2020 Aug;50(5):436-439
pubmed: 32305563
World J Otorhinolaryngol Head Neck Surg. 2018 Jun 05;4(1):33-38
pubmed: 30035259
Am J Rhinol. 2004 Jan-Feb;18(1):29-33
pubmed: 15035568
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Laryngoscope. 2015 Aug;125(8):1763-6
pubmed: 26031472
Laryngoscope. 2009 Mar;119(3):496-9
pubmed: 19235739
Perception. 2017 Mar-Apr;46(3-4):343-351
pubmed: 27703061
PLoS One. 2014 Oct 01;9(10):e107541
pubmed: 25271633
Acta Otolaryngol Suppl. 1998;538:197-201
pubmed: 9879420
Pediatrics. 2004 Sep;114(3):874-7
pubmed: 15342869
Clin Otolaryngol. 2017 Jun;42(3):557-563
pubmed: 27860366
Arch Otolaryngol Head Neck Surg. 1991 May;117(5):519-28
pubmed: 2021470
Am J Otolaryngol. 2017 Mar - Apr;38(2):143-147
pubmed: 27923495
Acta Otolaryngol. 2002 Dec;122(8):877-81
pubmed: 12542209
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Int Forum Allergy Rhinol. 2016 Jul;6(7):760-7
pubmed: 26879592
Rhinology. 2012 Sep;50(3):284-9
pubmed: 22888485
Syst Rev. 2014 Apr 15;3:37
pubmed: 24731537
Laryngoscope. 2006 Oct;116(10):1858-63
pubmed: 17003712
Indian J Otolaryngol Head Neck Surg. 2011 Jan;63(1):5-9
pubmed: 22319709
Otolaryngol Head Neck Surg. 2013 Jan;148(1 Suppl):S1-55
pubmed: 23243141
Int Forum Allergy Rhinol. 2020 Aug;10(8):944-950
pubmed: 32301284
Acta Otolaryngol Suppl. 1998;538:202-4
pubmed: 9879421
Int Forum Allergy Rhinol. 2018 Sep;8(9):977-981
pubmed: 29901865
Laryngoscope. 2014 Apr;124(4):826-31
pubmed: 23929687
Laryngoscope. 2002 Nov;112(11):2076-80
pubmed: 12439184
Arch Otolaryngol. 1962 Feb;75:116-24
pubmed: 13888447
Neural Plast. 2014;2014:140419
pubmed: 25544900
Evid Based Complement Alternat Med. 2016;2016:4986034
pubmed: 27034689
J Am Geriatr Soc. 2014 Feb;62(2):384-6
pubmed: 24521370
Laryngoscope. 2013 Dec;123(12):E85-90
pubmed: 24114690
Rhinology. 2016 Jun;54(2):170-5
pubmed: 27017331
Am J Med Sci. 1976 Nov-Dec;272(3):285-99
pubmed: 797259
Rhinology. 2016 Dec 1;54(4):368-374
pubmed: 27316224
Otolaryngol Head Neck Surg. 2010 Apr;142(4):505-9
pubmed: 20304268
Chem Senses. 2016 Jul;41(6):479-86
pubmed: 27170667
Chem Senses. 2005 Jan;30 Suppl 1:i212-3
pubmed: 15738120
Arch Otolaryngol Head Neck Surg. 2009 Oct;135(10):1000-4
pubmed: 19841338
Ear Nose Throat J. 2012 May;91(5):198-203, 215
pubmed: 22614554
Int Forum Allergy Rhinol. 2020 Sep;10(9):1065-1086
pubmed: 32567798
Arch Otolaryngol Head Neck Surg. 2006 Mar;132(3):265-9
pubmed: 16549746
Laryngoscope. 2011 Mar;121(3):679-82
pubmed: 21287560
Eur Arch Otorhinolaryngol. 2014 Jun;271(6):1557-62
pubmed: 24096819
Acta Otolaryngol. 2003 Sep;123(7):862-8
pubmed: 14575403
Int Forum Allergy Rhinol. 2011 Nov-Dec;1(6):431-7
pubmed: 22144051
Otolaryngol Head Neck Surg. 2017 Feb;156(2):371-377
pubmed: 28145844
Front Neurosci. 2020 Feb 21;14:140
pubmed: 32153360
Rhinology. 2015 Dec;53(4):371-8
pubmed: 26275583
Laryngoscope. 2012 Sep;122(9):1906-9
pubmed: 22752966